No link between cancer and tumor necrosis factor inhibitor TNFi use in psoriatic arthritis

No link between cancer and tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis

(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) suggest that overall cancer risk is not linked to tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis.

More From BioPortfolio on "No link between cancer and tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis"